Terns Pharmaceuticals Inc. announced the appointment of Erin Quirk, M.D., as Chief Medical Officer (CMO). Dr. Quirk brings more than two decades of clinical medicine and drug development experience, most recently serving as Vice President of Clinical Research at Gilead Sciences. Previously Dr. Quirk was Vice President, Clinical Research at Gilead Sciences where she oversaw all phases of clinical development for Gilead’s HIV treatment, prevention and cure franchise and was responsible for strategy and life cycle maintenance for the company’s HIV portfolio, advancing multiple compounds and combination products into clinical development and through the approval process. She also led the clinical development of small molecules within Gilead’s emerging and neglected viral diseases portfolio, including antivirals for Ebola virus disease. Prior to joining Gilead, Dr. Quirk was Director of Clinical Research at Merck where she advanced clinical trials for Merck’s investigational HIV vaccine products and oversaw the clinical development of small molecules for hepatitis C virus infection. Dr. Quirk holds an MD from the University of Colorado and completed training in internal medicine and infectious diseases at Washington University in St. Louis where she was a faculty member prior to joining the pharmaceutical industry.